A Phase I Dose Escalation Study of MK-8033 in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 29 Jan 2018
At a glance
- Drugs MK 8033; Omeprazole
- Indications Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 29 Jan 2018 Results assessing the safety and tolerability of MK-8033 in patients with metastatic or locally advanced solid tumors, were published in the Investigational New Drugs.
- 07 May 2012 Actual patient number (47) added as reported by ClinicalTrials.gov.
- 05 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.